Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Cherukuri Website

Murali Krishna Cherukuri, Ph.D.

Selected Publications

1)  Li F, Pang X, Krausz KW, Jiang C, Chen C, Cook JA, Krishna MC, Mitchell JB, Gonzalez FJ, Patterson AD.
Stable Isotope- and Mass Spectrometry-based Metabolomics as Tools in Drug Metabolism: A Study Expanding Tempol Pharmacology.
J. Proteome Res. 12: 1369-76, 2013.
[Journal]
2)  Subramanian S, Devasahayam N, Matsumoto S, Saito K, Mitchell JB, Krishna MC.
Echo-based Single Point Imaging (ESPI): a novel pulsed EPR imaging modality for high spatial resolution and quantitative oximetry.
J. Magn. Reson. 218: 105-14, 2012.
[Journal]
3)  Krishna MC, Matsumoto S, Yasui H, Saito K, Devasahayam N, Subramanian S, Mitchell JB.
Electron paramagnetic resonance imaging of tumor pO2.
Radiat. Res. 177: 376-86, 2012.
[Journal]
4)  Matsumoto S, Saito K, Yasui H, Morris HD, Munasinghe JP, Lizak M, Merkle H, Ardenkjaer-Larsen JH, Choudhuri R, Devasahayam N, Subramanian S, Koretsky AP, Mitchell JB, Krishna MC.
EPR oxygen imaging and hyperpolarized (13) C MRI of pyruvate metabolism as noninvasive biomarkers of tumor treatment response to a glycolysis inhibitor 3-bromopyruvate.
Magn Reson Med. [Epub ahead of print], 2012.
[Journal]
5)  Subramanian S, Chandramouli GV, McMillan A, Gullapalli RP, Devasahayam N, Mitchell JB, Matsumoto S, Krishna MC.
Evaluation of partial k-space strategies to speed up time-domain EPR imaging.
Magn Reson Med. [Epub ahead of print], 2012.
[Journal]
6)  Thavavel V, Basha J, Krishna M, Murugesan R.
Heuristic wavelet approach for low-dose EPR tomographic reconstruction: An applicability analysis wth phantom and in vivo imaging.
Expert Syst Appl. 39: 5717-5726, 2012.
[Journal]
7)  Saito K, Matsumoto S, Yasui H, Devasahayam N, Subramanian S, Munasinghe JP, Patel V, Gutkind JS, Mitchell JB, Krishna MC.
Longitudinal imaging studies of tumor microenvironment in mice treated with the mTOR inhibitor rapamycin.
PLoS ONE. 7: e49456, 2012.
[Journal]
8)  Subramanian S, Devasahayam N, McMillan A, Matsumoto S, Munasinghe JP, Saito K, Mitchell JB, Chandramouli GV, Krishna MC.
Reporting of quantitative oxygen mapping in EPR imaging.
J. Magn. Reson. 214: 244-51, 2012.
[Journal]
9)  Sourbier C, Srivastava G, Ghosh MC, Ghosh S, Yang Y, Gupta G, Degraff W, Krishna MC, Mitchell JB, Rouault TA, Linehan WM.
Targeting HIF2a translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Oncotarget. 3: 1472-82, 2012.
[Journal]
10)  Mitchell JB, Anver MR, Sowers AL, Rosenberg PS, Figueroa M, Thetford A, Krishna MC, Albert PS, Cook JA.
The antioxidant tempol reduces carcinogenesis and enhances survival in mice when administered after nonlethal total body radiation.
Cancer Res. 72: 4846-55, 2012.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 4/8/2013.